作者
Valentina Audrito, Antonella Managò, Sofia La Vecchia, Federica Zamporlini, Nicoletta Vitale, Gianna Baroni, Simona Cignetto, Sara Serra, Cinzia Bologna, Aureliano Stingi, Francesca Arruga, Tiziana Vaisitti, Daniela Massi, Mario Mandalà, Nadia Raffaelli, Silvia Deaglio
发表日期
2018/3/1
期刊
JNCI: Journal of the National Cancer Institute
卷号
110
期号
3
页码范围
290-303
出版商
Oxford University Press
简介
Background
One of the effects of oncogenic signaling is metabolic reprogramming of tumor cells to support anabolic growth, opening the way to therapeutic targeting of metabolic pathways.
Methods
We studied NAD biosynthesis in BRAF inhibitor (BRAFi)–resistant (BiR) melanoma cell lines. Data in cell lines were confirmed by immunohistochemistry in biopsies from 17 patients with metastatic melanoma (MM) before and after the acquisition of resistance to BRAFi. Therapeutic potential of NAD biosynthesis inhibitors was determined by in vitro monitoring cell growth and death and in mouse xenograft models. Mice (n = 6–10 mice/group) were treated with nicotinamide phosphoribosyltranferase inhibitor (NAMPTi), BRAFi, or their combination, and tumor growth and survival were analyzed. All statistical tests were two-sided.
Results
BiR cells had higher …
学术搜索中的文章
V Audrito, A Managò, S La Vecchia, F Zamporlini… - JNCI: Journal of the National Cancer Institute, 2018